Biofrontera (BFRI) said Thursday it received US patent approval for the revised formulation of Ameluz, extending protection through to December 2043.
Ameluz is a topical gel used in photodynamic therapy to treat actinic keratoses and certain basal cell carcinomas.
Biofrontera is also studying the medicine for the treatment of moderate to severe acne vulgaris. The company said it had enrolled the final patient in the phase 2b clinical trial of the drug, for a total of 120 subjects.
The company anticipates last-patient-out in Q3, it said.
Shares of Biofrontera were up 1.6% in recent trading.
Price: 0.71, Change: +0.01, Percent Change: +1.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。